Efficacy of third-line tyrosine kinase inhibitors (nilotinib, ponatinib, dasatinib, bosutinib and imatinib) in patients with chronic myeloid leukemia
Latest Information Update: 12 Jan 2021
Price :
$35 *
At a glance
- Drugs Bosutinib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 12 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology